home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies | Benzinga

Clinical-stage biotech innovator BioRestorative Therapies (NASDAQ:BRTX) recently announced that it is entering a new program of preclinical metabol...
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today | Benzinga

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.32% on an annualized basis producing an average annual return of 20...

JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage' | Benzinga

JPMorgan Chase & Co.’s (NYSE:JPM) asset management division has reportedly secured over $500 million for a biotech venture capital fund f...

Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report | Benzinga

Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) is reportedly set to overtake Denmark’s iconic toymaker, Lego A/S, as the nation’s mos...
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation' | Benzinga

Jim Cramer has expressed his confidence in Eli Lilly and Co (NYSE:LLY), citing the company’s diverse drug portfolio and the recent endorsemen...

Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge | Benzinga

U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, W...

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential | Benzinga

With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have s...
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits | Benzinga

The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. Wh...

Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market | Benzinga

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its...

British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy | Benzinga

Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
Next 10